Compare Pfizer Inc (PFE) vs Snap On Incorporated (SNA) Price & Performance

Pfizer (PFE) trades at $24.75, down 1.2% on the day, with a neutral technical outlook. The company maintains strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $0.75 beating expectations of $0.722. Pfizer demonstrates robust profitability with a 73.51% gross margin and 11.83% net income margin, though revenue has moderated from pandemic peaks. Recent news highlights the company's focus on AI drug discovery and pipeline development.

Pfizer presents a value opportunity trading below analyst consensus target of $28.25, with 38% of analysts rating it Buy. The stock offers a solid dividend yield with recent $0.43 payments. Key risks include patent expirations and revenue normalization post-COVID, while catalysts include obesity and oncology pipeline developments in 2026.

Snap-on Incorporated (SNA) trades at $406.53, down 1.09% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $407.50. The company reported strong 2025 results with $5.16B revenue and $1.02B net income, maintaining robust profitability margins. Recent strategic acquisitions like Diesel Laptops for $100M aim to expand its heavy-duty diagnostics capabilities, supporting future growth.

The outlook is positive given solid fundamentals and analyst support, but risks include potential margin pressures and reliance on automotive demand. With 64.71% of analysts rating it a buy and a dividend yield supported by recent declarations, SNA presents a stable investment opportunity tempered by industry cyclicality.